Editing Psilocybin (section)

==Contraindications==
[[Contraindication]]s of psilocybin are mostly [[psychiatric condition]]s that increase the risk of [[psychological distress]], including the rare [[adverse effect]] of [[psychosis]] during or after the psychedelic experience.<ref name="MacCallumLoPistawka2022" /><ref name="SabéSulstarovaGlangetas2025">{{cite journal | vauthors = Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll CU, Solmi M, Kaiser S, Kirschner M | title = Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies | journal = Mol Psychiatry | volume = 30 | issue = 3 | pages = 1223–1255 | date = March 2025 | pmid = 39592825 | pmc = 11835720 | doi = 10.1038/s41380-024-02800-5 | url = }}</ref> These conditions may include history of psychosis, [[schizophrenia]], [[bipolar disorder]], or [[borderline personality disorder]].<ref name="MacCallumLoPistawka2022" /><ref name="DowneyBradleyLerche2024">{{cite journal | vauthors = Downey AE, Bradley ER, Lerche AS, O'Donovan A, Krystal AD, Woolley J | title = A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy? | journal = Psychedelic Med (New Rochelle) | volume = 2 | issue = 2 | pages = 61–73 | date = June 2024 | pmid = 40051581 | doi = 10.1089/psymed.2023.0051 | pmc = 11658676 | pmc-embargo-date = June 17, 2025 | url = https://odonovanlab.ucsf.edu/sites/g/files/tkssra7476/f/Downey%2C%20A.%20E.%20-%20A%20Plea%20for%20Nuance_%20Should%20People%20with%20a%20Family%20History%20of%20Bipolar%20Disorder%20Be%20Excluded%20from%20Clinical%20Trials%20of%20Psilocybin%20Therapy_.pdf#page=2}}</ref> Further research may provide more [[drug safety|safety]] information about the use of psilocybin in people with such conditions.<ref name="MacCallumLoPistawka2022" /> It is notable in this regard that psilocybin and other psychedelics are being studied for the potential treatment of all the preceding conditions.<ref name="YaoGuoLu2024" /><ref name="WolfSinghBlakolmer2023">{{cite journal | vauthors = Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, Lotan A, Lerer B | title = Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation | journal = Mol Psychiatry | volume = 28 | issue = 1 | pages = 44–58 | date = January 2023 | pmid = 36280752 | doi = 10.1038/s41380-022-01832-z | url = }}</ref><ref name="SapienzaMartiniComai2025">{{cite journal | vauthors = Sapienza J, Martini F, Comai S, Cavallaro R, Spangaro M, De Gregorio D, Bosia M | title = Psychedelics and schizophrenia: a double-edged sword | journal = Mol Psychiatry | volume = 30 | issue = 2 | pages = 679–692 | date = February 2025 | pmid = 39294303 | doi = 10.1038/s41380-024-02743-x | url = }}</ref><ref name="Maćkowiak2023">{{cite journal | vauthors = Maćkowiak M | title = Psychedelics action and schizophrenia | journal = Pharmacol Rep | volume = 75 | issue = 6 | pages = 1350–1361 | date = December 2023 | pmid = 37899392 | pmc = 10661800 | doi = 10.1007/s43440-023-00546-5 | url = }}</ref><ref name="BoschHalmSeifritz2022">{{cite journal | vauthors = Bosch OG, Halm S, Seifritz E | title = Psychedelics in the treatment of unipolar and bipolar depression | journal = Int J Bipolar Disord | volume = 10 | issue = 1 | pages = 18 | date = July 2022 | pmid = 35788817 | pmc = 9256889 | doi = 10.1186/s40345-022-00265-5 | doi-access = free | url = }}</ref><ref name="CarrithersRobertsWeiss2025">{{cite journal | vauthors = Carrithers BM, Roberts DE, Weiss BM, King JD, Carhart-Harris RL, Gordon AR, Pagni BA, Moreau M, Ross S, Zeifman RJ | title = Exploring Serotonergic Psychedelics as a Treatment for Personality Disorders | journal = Neuropharmacology | volume = | issue = | pages = 110413 | date = March 2025 | pmid = 40081794 | doi = 10.1016/j.neuropharm.2025.110413 | url = }}</ref>

Psilocybin is also considered to be contraindicated in women who are [[pregnancy|pregnant]] or [[breastfeeding]] due to insufficient research in this population.<ref name="MacCallumLoPistawka2022" /> There are transient increases in [[heart rate]] and [[blood pressure]] with psilocybin, and hence uncontrolled [[cardiovascular condition]]s are a relative contraindication for psilocybin.<ref name="MacCallumLoPistawka2022" /> [[Serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[receptor antagonist|antagonist]]s such as [[atypical antipsychotic]]s and certain [[antidepressant]]s may block psilocybin's hallucinogenic effects and hence may be considered contraindicated in this sense.<ref name="HalmanKongSarris2024" /><ref name="YatesMelon2024" /> [[Monoamine oxidase inhibitor]]s (MAOIs) may potentiate psilocybin's effects and augment its risks.<ref name="HalmanKongSarris2024" />